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Structured Abstract 
Purpose of review: To provide an overview of POEMS syndrome, detailing new insights into 
pathogenesis, prognostic factors, treatments and outcome scores.  
 
Recent findings: With the development of large multi-centre national cohorts of patients, POEMS 
syndrome is evolving into a well characterised multi-system haematoneurological syndrome. 
Without early diagnosis significant disability results from the neuropathy. VEGF is a useful and 
accurate biomarker supporting diagnosis and following disease activity. The past decade has seen a 
number of therapeutics become available to POEMS patients, repurposed from myeloma treatment. 
Simple treatment algorithms are based on the extent of monoclonal proliferation and the 
performance status of patients. Risk factors, prognostic scores and their impact on outcome 
measures have been developed from deeply phenotyped patient cohorts to predict response rate, 
progression free and overall survival.  
 
Summary: Understanding links between the monoclonal lambda plasma cell disorder and resulting 
proinflammatory cytokine milieu is fundamental to determining POEMS syndrome pathophysiology. 
Similarities to CIDP and some other monoclonal proliferative diseases makes POEMS misdiagnosis 
common. A range of treatments are available, and more work to identify pathogenic mechanisms 
and treatment targets as well as prognostic scores will further enable treatment stratification for 
optimum outcomes.  
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Introduction 
Polyneuropathy Organomegaly Endocrinopathy M-Protein and Skin Changes (POEMS) syndrome is a 
rare multisystem autoinflammatory disease. Initially described by Crow and Fukase1 the disease 
describing acronym was coined by Bardwick in 19802. Although still thought to be rare it is 
increasingly recognised in a number of presenting forms mainly through neurology and haematology 
referral sources.  
Significant contributions to the diagnosis and management of POEMS have been made over a 
number of years through the work of the Dispenzieri (USA), Kuwabara (Japan) and Li (China) groups 
alongside other important smaller groups in France and Italy. These include the definition of core 
sets of diagnostic criteria 3, the identification of VEGF as a major biomarker for the disease4–7, 
contributions to epidemiology and diagnostic findings 3,8–16 as well as a number of studies informing 
current treatments and outcomes7,17–33.  
As a result of these dedicated studies in a rare disease, the successful diagnosis and treatment of 
POEMS syndrome is probably more frequent in generalist settings. However, referral to specialist 
centres with access to autologous stem cell transplantation and specialist immunomodulatory 
haematology drugs as well as structured rehabilitation and follow up monitoring is recommended.    
Text of Review 
Epidemiology 
POEMS syndrome is a rare disease and the exact incidence and prevalence are unknown. Studies 
reporting the largest cohorts of POEMS patients are in America (291 patients) 26 and China (476 
patients) 7. Other studies over 5 years old described 102 patients in Japan8, 25 in France10 and 29 in 
India34. Such figures are unlikely to accurately reflect the epidemiology but do suggest POEMS is 
possibly more common in China and Japan than Europe and the USA. POEMS is about 2 ½ times 




The pathophysiology of POEMS syndrome remains poorly understood (see Figure 1). POEMS is 
intrinsically linked to the presence of the monoclonal plasma cell disorder and a co-existing 
upregulation of pro-inflammatory cytokines, resulting in a host of downstream multi-system effects. 
Small volume malignant plasma cell clones are thought to drive the disease. However, little is known 
about the pathogenic role of these plasma cells. Of notable interest is that they are lambda light 
chain restricted in over 95% of cases 35. Furthermore there is restricted usage of immunoglobulin λ 
light chain variable region (IGLV) genes, strictly derived from IGLV 1-40 and 1-4436,37, suggestive of 
some antigenic affinity maturation. A number of common cytogenetic abnormalities found in 
multiple myeloma are also associated with POEMS causation and prognosis; aneuploidy including 
monosomy 13 and trisomy 3 and 738 and 14q32 translocations and 13q14 deletions have all been 
described16 illustrating similarities of the underlying pathogenesis. Drawing together the various 
malignant and immune driven mechanisms remains an incomplete task.  
Vascular Endothelial Growth Factor is a potent angiogenic proinflammatory cytokine found markedly 
raised in POEMS syndrome5. VEGF correlates both with disease activity5 and predicts treatment 
response and survival7 . Wang et al. recently demonstrated bone marrow plasma cells as the primary 
source of VEGF measured at both mRNA and protein levels, the levels decrease markedly following 
treatment 39. Interestingly polyclonal plasma cells secrete the greatest amount of VEGF, whereas the 
small populations of monoclonal cells are strongly IL6 positive. Monoclonal cell derived IL6 may drive 
polyclonal plasma cell VEGF release. Since polyclonal plasma cells are more sensitive to 
chemotherapy this may explain the relative ease of obtaining complete VEGF suppression but less 
frequent complete haematological response.  
VEGF has multiple roles including as a growth factor for endothelial cells, and an important regulator 
of osteogenesis. Excess VEGF probably plays a pathogenic role in extravascular volume overload, 
bone lesions, papilloedema, glomerular haemangiomata and arteriopathy in POEMS. VEGF also 
causes microvascular permeability and endoneurial damage, and leakage of toxic serum components 
is postulated to cause the neuropathy; more work is needed to prove this pathologically11. Wang et 
al. have demonstrated that polyclonal bone marrow cells produce the largest proportion of VEGF as 
opposed to the abnormal monoclonal cell population. Polyclonal cells are thought to be more 
sensitive to chemotherapy, which may explain why VEGF suppression often occurs in POEMS 
syndrome despite persistence of the monoclonal protein39.  
Despite a focus on VEGF, it is unlikely to be the major pathogenic mediator. Supressing VEGF alone 
with bevacizumab does not lead to clinical recovery of POEMS syndrome and may be harmful32, 
suggesting that whilst VEGF is a downstream mediator of some disease features, it is not an initiating 
factor in POEMS pathogenesis. Alterations in pro-inflammatory cytokines such as fibroblast growth 
factor, hepatocyte growth factor, tumour necrosis factor, interleukin (IL) 6, IL 12, HIF1α and N-
terminal propeptide of type I collagen have been reported in POEMS syndrome40–42, but more 
research is required to understand their roles in pathogenic mechanisms.  
 
Diagnosis  
Because each major feature of the disease is relevant to disparate medical specialties, the diagnosis 
is often delayed by a failure to recognise the diagnostic features outside the immediate sphere of 
knowledge of the specialty. The most recent diagnostic criteria have been published by Dispenzieri 
et al.43 and details of the major diagnostic criteria are below. 
 
Polyneuropathy 
The most disabling feature of POEMS is the demyelinating neuropathy, frequently misdiagnosed as 
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). However early in the disease 
there is seldom any proximal weakness and throughout the disease course striking distal weakness 
of the hands and feet predominates44. A typical POEMS neuropathy is a symmetrical, sensorimotor 
length dependent painful neuropathy which progresses proximally over time and is resistant to 
plasma exchange and IVIG3,8,10. Albuminocytological dissociation occurs as in CIDP. Typical 
electrophysiological features (see below) help support clinical findings. Any patient with an 
apparently treatment resistant ‘CIDP’ should be evaluated for POEMS syndrome. 
 
OEMS and others 
Small numbers of patients, especially those with Castleman Disease can have very mild distal sensory 
loss or even no demonstrable neuropathy despite fulfilling many or all of the other criteria45. These 
patients may complain of neuropathic symptoms despite entirely normal neurological examinations 
by competent neurologists and normal electrophysiology. It is not known if these patients eventually 
develop the polyneuropathy.   
Electrophysiology 
Neurophysiology in POEMS syndrome fulfils diagnostic criteria for CIDP in 70% of cases46 highlighting 
difficulties with both clinical diagnosis and the criteria. Several studies have tried to distinguish the 
neurophysiological characteristics of POEMS syndrome from CIDP. Slowed conduction velocity with 
marked early secondary axonal loss is typical. Motor conduction velocities (MCV) are equally 
reduced in the upper and lower limbs, and velocities are often slower than CIDP. Uniform 
demyelination along the nerve with no conduction block (10% compared to 45% in CIDP47), normal 
terminal latency indices (TLi) and F-wave delay proportionate to MCV slowing, as opposed to focal 
involvement of selected fibres in CIDP is the norm.47–50 At diagnosis, approximately 50% of nerves 
with reduced motor conduction velocity MCV have reduced CMAP amplitude50. CMAPs in the lower 
limbs are more severely affected than the upper limbs, with abnormal values in 96% peroneal, 97% 
tibial, 65% ulnar and 67% median nerves tested in 138 POEMS patients, with 108 and 104 absent 
responses in the peroneal and tibial nerves respectively48. Compared with CIDP, POEMS patients 
have a far greater reduction in CMAPs, particularly in the lower limbs (peroneal p<0.0001, tibial 
p<0.001) reflecting more significant secondary axonal loss. Being a length dependent process, sural 
sparing is not seen in POEMS syndrome as it sometimes is in CIDP48.  
In the realm of paraprotein associated neuropathies, the  neurophysiology of POEMS compared to a 
neuropathy  associated with monoclonal gammopathy of unknown significance (MGUS), both exhibit 
demyelinating features with reduced conduction velocities, prolonged distal motor latencies and 
prolonged F-waves. However POEMS demonstrates greater reduced upper and lower limb CMAPs 
and a greater reduction of median and ulnar MCVs, and the TLI is higher, suggesting slowing is 
greater in intermediate than distal nerve segments51. 
 
Monoclonal plasma cell disorder 
The POEMS serum paraprotein may be of very low level and is frequently undetectable if sought 
only by serum protein electrophoresis (SPEP). SPEP is positive in as few as 54% of cases, with higher 
yield on immunofixation (75-92%). Over 95% of cases are lambda light chain restricted3,8. Urine 
protein electrophoresis and immunofixation may identify an M-protein when serological 
investigations are negative.  A monoclonal plasma cell disorder may possibly only be detectable 
when a high level of suspicion about the diagnosis results in a bone marrow, lymph node or lesional 
bone biopsy revealing light chain restricted B-Cells or Castleman Disease. Identification and choice of 
target lesion is greatly assisted by fluorodeoxyglucose (FDG)-PET scanning, which should be part of 
the diagnostic workup in every suspected case14.  
 
Multisystem features 
A host of multisystem features occur at different frequencies in POEMS syndrome, with most 
patients at diagnosis presenting with 5-6 features.3 Organomegaly is rarely palpable and identified 
on imaging. Diabetes and thyroid abnormalities are too prevalent in the general population to be 
considered a diagnostic feature, unless developed at the onset of other characteristic features. 
Endocrinopathy features are variable, and therefore systematic screening at diagnosis and 
monitoring is necessary. Skin abnormalities are present in 70% of our cohort (unpublished data), 
including plethora, acrocyanosis, hypertrichosis, skin thickening, nail changes and glomerular 
haemangiomata. The acronym ‘PEST’, relating to papilloedema, extravascular volume overload, 
sclerotic bone lesions and thrombocytosis is a useful aide memoire. Cardiopulmonary manifestations 
of heart failure, pulmonary hypertension, restrictive lung disease  and renal disease impact on 
patients general fitness, ability to tolerate autologous stem cell transplantation52,53 and overall 




Organomegaly, bone marrow infiltration and extravascular volume overload are useful diagnostic 
features of POEMS syndrome identified through radiological investigation. Developments in imaging 
mean skeletal surveys are now less frequently used, whereas CT, MRI and FDG-PET are increasingly 
important although it is unclear which modality is most accurate. CT imaging can identify bone 
lesions and important systemic features such as pleural effusions, ascites, adenopathies and 
organomegaly.  The ability of FDG-PET to identify FDG-avid bone lesions, often representative of 
active infiltration with plasma cells, is useful in the diagnosis in POEMS as it guides targeted lesional 
biopsy14 as well as determining focal or systemic therapy decisions. Furthermore, avidity changes in 
bones occur sooner than bone changes seen on CT, and may correlate with other favourable post 
treatment response indicators14. 
 
POEMS is largely a peripheral nervous system disease. However stroke is not an uncommon 
presenting feature, although the pathogenesis of POEMS strokes is not understood54. 
Hypercoagulability related to raised VEGF, platelet instability, HIF1a induction, microvascular 
endothelial swelling, vascular leak (see Figure 1), the presence of a paraprotein and the additional 
treatment related pro-coagulant effects of lenalidomide may result in vascular occlusion with 
unusual features on brain imaging. A further recent observation of frequent asymptomatic 
pachymeningitis is an interesting and previously unreported finding in a significant proportion of 
patients55.  
   
Treatment 
POEMS is a treatable disease. Untreated the median survival is 33 months, but recent studies of 138 
and 362 patients from two large series stratified into good and poor pre-treatment prognosis have 
demonstrated 5 year survival rates of 79% and 84% and 10 year survival of 62% and 77% 20,26. Even 
poor prognosis patients had a 71% survival at 5 years. The keys to successful treatment outcomes 
are the recognition of the disease, rapid diagnosis and early intervention before irreversible 
neurological disabilities occur. 
Treatment options are relatively straightforward, with simple algorithms to guide decision making35. 
Treatment of POEMS is aimed at the clonal haematologic disease and the cytokine drive as well as 
supportive care largely for the neurological and endocrine consequences of the disease once the 
acute management of the unwell presenting patient and the definitive disease directed treatment is 
over. The medical treatment of POEMS is summarised in a recent paper by Jaccard56.  
Radiotherapy 
Where there is no bone marrow involvement and there are 3 or fewer bone lesions, curative 
radiotherapy doses of 40Gy or more to the solitary myeloma is indicated. Six year progression free 
survival of 82 patients treated at the Mayo Clinic with radiotherapy, each of whom had between 1 
and 3 lesions, was 62 % 57. There was no difference between those with one, two or three lesions. 
Radiotherapy is somewhat slow to work and may be given with either dexamethasone (40mg per 
day for 4 days every 2 weeks), or more recently with lenalidomide and dexamethasone with good 
results58.  
Autologous stem cell transplantation 
Autologous stem cell transplantation (ASCT) is the treatment of choice where radiotherapy is not 
suitable and where the physical performance status of the patient allows. Priming with 
dexamethasone58, thalidomide or lenalidomide or combinations18,23  may protect against acute 
engraftment syndrome. Engraftment syndrome occurs 7-15 days after transplant and comprises 
fluid overload and weight gain, respiratory compromise, skin eruptions and diarrhoea and can be 
fatal. Most ASCT is performed as Melphalan 140- or 200-Conditioned regimens, and has the highest 
progression free and overall survival from all the treatment modalities; five year overall survival is 
reported at 90-95%, and five year PFS at 63-76%17–19,23,26. Studies have demonstrated reduced rates 
of engraftment syndrome with 4 days of 40mg dexamethasone56, or lenalidomide17 between stem 
cell collection and ASCT. 
If patients are deemed too unwell to tolerate ASCT (for example age over 70 or significant cardio-
respiratory compromise), then systemic chemotherapy can either be used as a long-term treatment, 
or as a bridging therapy to optimise patients for ASCT at a later date.  There are no established 
guidelines for exactly which chemotherapy to choose or which is most efficacious, but the following 
is a broad guide. 
Melphalan  
One prospective trial of Melphalan in POEMS syndrome has been published59. Thirty-one patients 
received 12 cycles of melphalan and dexamethasone treatment. Twenty-five (81%) achieved 
haematologic response including 38% complete response; 100% had VEGF reduction. There was 
improvement in ONLS score in all patients within 15 months, and all patients were alive without 
progression at median follow up of 21 months.  
 
Cyclophosphamide  
Retrospective cyclophosphamide treated POEMS cohorts have been described, but no prospective 
trials exist. 28% of the Mayo Clinic cohort were treated with non-transplant dose alkylator 
chemotherapy26 and 23% in the Japanese cohort8. Alkylator based therapy data tends to be grouped 
with all chemotherapeutics and has worst overall survival (10-year OS 46% at the Mayo Clinic) 
especially compared to ASCT and radiotherapy). This might be attributable to selection bias and poor 




The Japanese POEMS Syndrome with Thalidomide (J-POST) trial of 25 POEMS patients demonstrated 
thalidomide 100-300mg/day plus dexamethasone had greater VEGF reduction and possible 
improvement in motor function compared to dexamethasone alone 27. This is further supported by a 
number of prospective trials, case series and derived best practice guidelines56. Thalidomide at a 
cumulative dose of more than 50g causes neuropathy which may confound improvement in 
neurological function.  
 Lenalidomide 
Anecdotally, lenalidomide appears to be the most efficacious chemotherapeutic or 
immunomodulatory agent in POEMS syndrome to date, with reports of rapid resolution of volume 
overload and VEGF, improvement of neuropathy and haematological response. A systematic review 
of lenalidomide in 51 POEMS patients demonstrated at least very good partial response in 58% and 
partial response in 37%. VEGF was reduced in all cases, and neuropathy improved in 92%. An 
estimate of PFS at 12 months was 94%60. A prospective trial of lenalidomide and dexamethasone in 
18 patients found clinical and neurological improvement with all patients alive at a median follow up 
of 39 months and a 3-year PFS of 59%24. Li et al. studied 138 patients with POEMS and ASCT; of 
those, 32 patients initially deemed unfit for ASCT were treated with lenalidomide which made 
subsequent ASCT feasible. Cai et al. have also demonstrated effectiveness of lenalidomide in 12 
patients with relapsed disease29. A low dose lenalidomide regimen of 10mg per day has non-inferior 
response outcomes and much better safety in a prospective phase II study of 41 patients published 
in 201861  Lenalidomide is prothrombotic and therefore should be used in caution in patients with 
evidence of venous or arterial thrombosis, thrombocytosis or polycythaemia, all recognised 
associations with POEMS syndrome.  
 
Bortezomib  
He et al. have used bortezomib in combination with cyclophosphamide and dexamethasone in 20 
patients 21. Complete haematological response was seen in 41% and partial response in 35%. VEGF 
response was documented in 88%. Neurological response was measured by a median ONLS 
improvement from 5 pre-treatment, to 3 after treatment. In myeloma series neuropathy occurs as a 
result of bortezomib in 1/3 of cases and therefore may confound improvement. Carfilzomib, a 
second-generation proteasome inhibitor with fewer off target effects and much less neuropathy has 
not been studied in POEMS syndrome. The Mayo Clinic are currently recruiting patients to trial 
Ixazomib with lenalidomide and dexamethasone (NCT02921893) which will be of interest. 
 
Prognostic factors, outcomes and response scores 
The rich diversity of features in POEMS provides many candidates for biomarkers for prognosis and 
treatment response. Haemato-oncology studies concentrate on progression free (PFS) and overall 
survival (OS). High and low risk groups can be identified for PFS and OS from presenting features. 
Kourelis et al. studied the Mayo Clinic’s outcome data of 291 POEMS patients, and identified three 
factors associated with superior OS; younger age, serum albumin < 3.2g/dL and complete 
haematological response following treatment26. Similar risk factors apply to progression after first 
line treatment57. Wang et al. have developed a prognostic nomogram for POEMS patients, in which 
OS and PFS can be estimated through combining patient age, evidence of pulmonary hypertension, 
pleural effusion and estimated glomerular filtration rate20. Kourelis and Dispenzieri validated the 
nomogram in their Mayo cohort, suggesting it has external validity applicable to a broader patient 
population.25. Misawa et al. demonstrated normalisation of VEGF at 6 months post treatment 
correlated with prolonged relapse free survival, improved grip strength and CMAP amplitudes at 12 
months62. Zhao et al. have also cited the prognostic value of VEGF response alone, and in 
combination with haematological response as a surrogate endpoint in clinical trials7.   
 Summary 
POEMS syndrome is a rare condition which appears to be driven by a monoclonal lambda light chain 
restricted proliferative disorder, resulting in a proinflammatory response, and a range of 
downstream multisystem responses. VEGF is a key biomarker in diagnosis, response and relapse 
identification, but is not the only cytokine involved in pathogenesis. Treatment is directed at the 
monoclonal proliferative disorder, but this could change with the advent of prognostic nomograms 
to identify patients at risk of refractory disease and relapse. Currently, radiotherapy, 
chemotherapeutics and ASCT are appropriate therapies for POEMS syndrome, with more patients 
ultimately being treated with ASCT due to emerging efficacy of pre-optimisation protocols.  
 
Learning points 
1) POEMS is a rare disorder in which the pathogenesis is poorly understood, but thought to be 
intrinsically linked to the presence of the monoclonal plasma cell disorder and secondary to 
a number of inflammatory cytokines leading to a host of multi-system effects.  
2) Neuropathy in POEMS syndrome is typically symmetrical, sensorimotor, length dependent 
and painful.  
3) Typical neurophysiology in POEMS demonstrates conduction velocity slowing with marked 
secondary axonal loss, often with no responses in the lower limbs. Conduction block and 
temporal dispersion are uncommon when compared to CIDP. 
4) POEMS is treatable with favourable overall and progression free survival. Autologous stem 
cell transplantation provides the best outcomes but other methods such as radiotherapy and 
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Figure 1: A proposed pathogenesis of POEMS syndrome. Central to the pathogenesis is VEGF, 
although this is not the primary cause. Malignant clonal or autonomous plasma cells drive 
production of IL6 and proliferation of lymphoid stroma. Released cytokines are responsible for bone 
resorption and systemic features of disease. A procoagulant state driven by vascular endothelial 
swelling, platelet aggregation and tissue ischaemia drives HIF1α production which further drives 
VEGF production. Vascular leak leads to oedema, papilloedema, effusions and reduced lung transfer 
factors. VEGF drived lasma cell migration , proliferation, survival and release of further cytokines. 
VEGF – vascular endothelial growth factor, HIF1α – Hypoxia induced factor alpha-1, BNB- Blood 
nerve barrier, IL6 – interleukin-6, TNFα – tumour necrosis factor alpha. 
 
 
